Atabecestat

Atabecestat (JNJ-54861911) is a potent brain-penetrant and orally active β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor, achieves robust and high CSF Aβ reduction. Atabecestat s tolerated and displays a sustained pharmacokinetic (PK) and pharmacodynamic (PD) characteristics. Atabecestat has the potential for Alzheimer's Disease treatment[1].

Product Specifications

CAS Number

[1200493-78-2]

Product Name Alternative

JNJ-54861911

UNSPSC

12352005

Hazard Statement

H361-H373

Target

Beta-secretase

Type

Reference compound

Related Pathways

Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/atabecestat.html

Concentration

10mM

Purity

99.77

Solubility

DMSO : 250 mg/mL (ultrasonic)

Smiles

O=C(C1=NC=C(C#N)C=C1)NC2=CC=C(F)C([C@@]3(C)N=C(N)SC=C3)=C2

Molecular Formula

C18H14FN5OS

Molecular Weight

367.40

Precautions

P260-P280-P405-P501

References & Citations

[1]Timmers M, et al. Profiling the dynamics of CSF and plasma Aβ reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor.Alzheimers Dement (N Y) . 2016 Aug 24;2 (3) :202-212.|[2]Janssens J, et al. Passive immunotherapy with a novel antibody against 3pE-modified Aβ demonstrates potential for enhanced efficacy and favorable safety in combination with BACE inhibitor treatment in plaque-depositing mice. Neurobiol Dis. 2021 Jul;154:105365.